ClinicalTrials.gov
public full text
Public Domain
Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes
Insulin is a chemical that the body needs in order to use or store sugar. It is made by a type of cell called a beta cell which resides in an organ known as the pancreas. Type 1 diabetes is a disease where the beta cells have been destroyed so that little or no insulin is made. Sugar levels rise in the blood as a result. INGAP-Peptide is being tested to attempt to create new beta cells in the pancreas, and to restore the ability to produce insulin in type 1 diabetic patients.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes#801350
- Function of Beta Cells in Early-onset Diabetes Mellitus#325212
- Safety Study of Intranasal Insulin in Type 1 Diabetes and Diabetic Peripheral Neuropathy#668910
- GIP: Glucose-dependent Insulinotropic Peptide#1010944
- Rat INS-1E pancreatic beta cells#356429
Record · ID 1127179
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive